Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Parenteral iron therapy: problems and possible solutions]

R Hoigné1, C Breymann, U P Künzi

  • 1Ehemaliger ärztlicher Leiter, Schweizerische Stiftung, Comprehensive Hospital Drug Monitoring (CHDM), Bern/St. Gallen.

Schweizerische Medizinische Wochenschrift
|May 21, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low back pain patients with Modic type 1 changes exhibit distinct bacterial and non-bacterial subtypes.

Osteoarthritis and cartilage open·2024
Same author

Real-world analysis of teclistamab in 123 RRMM patients from Germany.

Leukemia·2024
Same author

Validity of outcome measures used in randomized clinical trials and observational studies in degenerative lumbar spinal stenosis.

Scientific reports·2023
Same author

FGF2 overrides key pro-fibrotic features of bone marrow stromal cells isolated from Modic type 1 change patients.

European cells & materials·2022
Same author

Water-window high harmonic generation with 0.8-µm and 2.2-µm OPCPAs at 100 kHz.

Optics express·2021
Same author

Pro-fibrotic phenotype of bone marrow stromal cells in Modic type 1 changes.

European cells & materials·2021

Parenteral iron preparations, including iron dextran and iron sucrose, show varying adverse drug reaction (ADR) frequencies. Intravenous iron sucrose appears well-tolerated, especially in patients with chronic renal insufficiency, suggesting potential for reduced preventive measures.

Area of Science:

  • Pharmacovigilance and Drug Safety
  • Clinical Pharmacology
  • Hematology

Context:

  • Adverse drug reactions (ADRs) to parenteral iron are a significant concern in clinical practice.
  • Different formulations, such as iron dextran and iron sucrose, are used for treating iron deficiency anemia.
  • Understanding the comparative safety profiles of these preparations is crucial for optimizing patient care.

Purpose:

  • To compare the frequency of adverse drug reactions (ADRs) associated with different parenteral iron preparations.
  • To specifically evaluate anaphylactic/anaphylactoid reactions and exanthemas with iron dextran and iron sucrose.
  • To assess the safety of intravenous iron sucrose in patients with anemia, particularly those with chronic renal insufficiency.

Summary:

  • A comparative analysis of four data collections revealed varying ADR frequencies for intramuscular (i.m.) iron dextran and intravenous (i.v.) iron sucrose.

Related Experiment Videos

  • Intravenous iron sucrose demonstrated a favorable safety profile, with a low incidence of severe reactions, especially in hemodialysis patients.
  • While some generalized skin reactions and transient blood pressure changes were noted with iron sucrose, life-threatening events were absent in chronic renal failure patients.

    • Impact:

    • The findings suggest that intravenous iron sucrose may be a safer alternative, particularly for patients with chronic renal insufficiency.
    • The study's results could lead to a reduction in preventive measures for intravenous iron sucrose administration in specific patient populations.
    • This research contributes to evidence-based guidelines for the safe and effective use of parenteral iron therapies.